08:39 AM EDT, 08/27/2025 (MT Newswires) -- MannKind ( MNKD ) said Wednesday that United Therapeutics ( UTHR ) has exercised its option to develop a second dry powder inhalation therapy under their 2018 license and collaboration agreement.

MannKind ( MNKD ) said it will receive $5 million upfront, and would be eligible to receive up to $35 million in development milestones and 10% royalties on net sales of any resulting product under the expanded agreement.

MannKind ( MNKD ) said it will immediately start formulating a second investigational molecule via its Technosphere platform. United Therapeutics ( UTHR ) will conduct preclinical and clinical development, it added.

Their collaboration led to the US Food and Drug Administration approval of Tyvaso DPI for pulmonary hypertension in May 2022, MannKind ( MNKD ) said.